UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): December 23, 2003

AMERICAN VANGUARD CORPORATION

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$

Delaware (State or other jurisdiction of incorporation)

0-6354 Commission File Number 95-2588080 (I.R.S. Employer Identification No.)

4695 MacArthur Court

Newport Beach, California 92660

(Address of principal executive offices)

Edgar Filing: AMERICAN VANGUARD CORP - Form 8-K

Registrant s telephone number: (949) 260-1200

Edgar Filing: AMERICAN VANGUARD CORP - Form 8-K

Item 5. Other Events.

On December 23, 2003, American Vanguard announced that AMVAC Chemical Corporation, a wholly owned subsidiary of the Company, completed the acquisition of certain assets related to the active ingredient dichlorvos (DDVP) used in the animal health business and marketed primarily under the trade name Nuvan from Novartis Animal Health, Inc., a business unit of Novarits AG. All more particularly described in Exhibit 99.1.

Item 7. Exhibits.

99.1 Press release issued December 23, 2003

Edgar Filing: AMERICAN VANGUARD CORP - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMERICAN VANGUARD CORPORATION

(Registrant)		
Ву:	/s/ James A. Barry	
	James A. Barry	_
	Senior Vice President	
	Chief Financial Officer	

Date: December 23, 2003

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Press release dated December 23, 2003, of American Vanguard Corporation.

4